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Introduction
iTeos leverages the science of the LICR to target the meta-
bolism of the tumor microenvironment and develops
small-molecule inhibitors. Tryptophan catabolism can
suppress the anti-tumor immune response through
expression of the rate-limiting enzyme IDO1. Local trypto-
phan reduction and metabolite production by the kynure-
nine pathway are associated with anergy/apoptosis of
tumor-infiltrating lymphocytes. Two IDO1 inhibitors
(Incyte INCB24360/NewLink NLG919) are currently
tested in clinical trials for treatment of relapsed/refractory
solid tumors but exhibit therapeutic limitations.
Methods/results
A primary HTS (176,000 compounds) led to the discov-
ery of several confirmed hits. Medicinal chemistry opti-
mization resulted in an original lead with nM potency
in a relevant human blood assay, comparable to Incyte
IDO1i (IC50 890 ± 220 nM [iTeos IDO1i] versus 970 ±
100 nM [Incyte IDO1i] [N = 3 donors; Kyn ELISA]). For
rodents & monkey, iTeos compound showed low clear-
ance (9.9&1.9 mL/min/kg respectively), moderate-to-low
protein binding (48&28%Fu respectively), a short half-
life in rodents but long in monkey (1.1&12 h respec-
tively), good oral availability (>75%), and no inhibition
on five CYP450 isoforms). Good predictive values for
human PK were obtained through allometric scaling.
Quantification of the tryptophan metabolite kynurenine
showed a significant decrease in mouse plasma after
oral administration of the IDO1i in a dose response set-
ting (45.3 ± 2.4 [iTeos IDO1i] and 48.1% ± 3.0 [Incyte
IDO1i]; 2 h per os at 100 mg/kg compared to vehicle; N
= 5 independent experiments). In a time-course experi-
ment, inhibition of kynurenine production lasted 8 h
(iTeos IDO1i) compared to 16 h (Incyte IDO1i),
consistent with their respective rodent half-life. A com-
parable PD effect was observed in mouse tumor lysates.
Monkey PD is ongoing. Preliminary data obtained with
the Pan02 mouse tumor model showed significant survi-
val benefit of the iTeos IDO1i in stand-alone and in
combination with anti-CTLA4 treatment compared to
vehicle or anti-CTLA4 in stand-alone respectively. 15
different human cancer types (60 samples each) were
analyzed for IDO1 protein expression and allowed iden-
tification of several tumors with high expression.
Conclusions
iTeos’ drug discovery efforts have delivered a selective
IDO1 small-molecule inhibitor with novel scaffold suita-
ble for in vitro/in vivo validation and with good predic-
tive human PK (low clearance(<10% QH), long half-life
(>20 h), high oral bioavailability).
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